New Drugs and Devices in the Pipeline for Heart Failure with Reduced Ejection Fraction Versus Heart Failure with Preserved Ejection Fraction

被引：13
作者：
Raina A. [1 ]
Kanwar M. [1 ]
机构：
[1] Cardiovascular Institute, Allegheny General Hospital, Pittsburgh
来源：
Current Heart Failure Reports | 2014年 / 11卷 / 4期
关键词：
Device therapy; Drug therapy; Heart failure; LVAD; Mechanical circulatory support;
D O I：
10.1007/s11897-014-0222-8
中图分类号：
学科分类号：
摘要：
Heart failure (HF) is a growing problem in the USA and other industrialized nations. HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) each make up approximately half of the overall HF burden. Although a variety of medical and surgical therapies exist for the treatment of patients with HFrEF, morbidity and mortality remain high, and cardiac transplantation, considered the current gold standard for patients with HFrEF and severe symptoms, is reserved for relatively few eligible patients. Patients with HFpEF have more limited therapeutic options, because no medical therapy to date has been shown to improve survival in these patients. With the rising prevalence of HF and its increasing role in health care expenditure, there is a substantial need for new drug and device therapies for HFrEF and, in particular, HFpEF. This forms the topic of the current review. © 2014, Springer Science+Business Media New York.
引用
收藏
页码：374 / 381
页数：7
相关论文
共 79 条
  • [21] Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure, N Engl J Med, 341, 10, pp. 709-717, (1999)
  • [22] Solomon S.D., Wang D., Finn P., Skali H., Zornoff L., McMurray J.J., Et al., Effect of candesartan on cause-specific mortality in heart failure patients: the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program, Circulation, 110, 15, pp. 2180-2183, (2004)
  • [23] Zannad F., McMurray J.J., Krum H., van Veldhuisen D.J., Swedberg K., Shi H., Et al., Eplerenone in patients with systolic heart failure and mild symptoms, N Engl J Med, 364, 1, pp. 11-21, (2011)
  • [24] Abraham W.T., Fisher W.G., Smith A.L., Delurgio D.B., Leon A.R., Loh E., Et al., Cardiac resynchronization in chronic heart failure, N Engl J Med, 346, 24, pp. 1845-1853, (2002)
  • [25] Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R., Et al., Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure, N Engl J Med, 352, 3, pp. 225-237, (2005)
  • [26] Bristow M.R., Saxon L.A., Boehmer J., Krueger S., Kass D.A., De Marco T., Et al., Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure, N Engl J Med, 350, 21, pp. 2140-2150, (2004)
  • [27] Moss A.J., Hall W.J., Cannom D.S., Daubert J.P., Higgins S.L., Klein H., Et al., Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia, N Engl J Med, 335, 26, pp. 1933-1940, (1996)
  • [28] Moss A.J., Hall W.J., Cannom D.S., Klein H., Brown M.W., Daubert J.P., Et al., Cardiac-resynchronization therapy for the prevention of heart-failure events, N Engl J Med, 361, 14, pp. 1329-1338, (2009)
  • [29] Moss A.J., Zareba W., Hall W.J., Klein H., Wilber D.J., Cannom D.S., Et al., Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction, N Engl J Med, 346, 12, pp. 877-883, (2002)
  • [30] Rose E.A., Gelijns A.C., Moskowitz A.J., Heitjan D.F., Stevenson L.W., Dembitsky W., Et al., Long-term use of a left ventricular assist device for end-stage heart failure, N Engl J Med, 345, 20, pp. 1435-1443, (2001)
12345678